Assessing the metabolism of the olfactory circuit by use of 18F-FDG PET-CT imaging in patients suspected of suffering from Alzheimer's disease or frontotemporal dementia

Alzheimers Res Ther. 2024 Oct 29;16(1):241. doi: 10.1186/s13195-024-01604-7.

Abstract

Purpose: The loss of olfactory function is known to occur in patients suffering from (behavioral variant) frontotemporal dementia ((bv)FTD) and Alzheimer's disease (AD), although different pathophysiological mechanisms underpin this clinical symptom in both disorders. This study assessed whether brain metabolism of the olfactory circuit as assessed by positron emission tomography (PET) imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose ([18F]-FDG) can distinguish these entities in different subsets of patients.

Methods: Patients presenting with cognitive decline were included from a prospectively kept database: (1) bvFTD patients, (2) AD patients and (3) patients with logopenic primary progressive aphasia (PPA). Metabolic rates were calculated for different regions of the olfactory circuit for each subgroup and compared with a cohort of subjects with normal brain metabolism. Additionally, in patients with a logopenic PPA pattern on PET-imaging, statistical parametric mapping (SPM) analysis was performed.

Results: The metabolism of subdivisions of the olfactory circuit as assessed by [18F]-FDG PET brain imaging to bvFTD and AD from control subjects resulted in sensitivity/specificity rates of 95/87.5% and 80/83.3%, respectively. A sensitivity/specificity rate of 100/87.5% was achieved when used to differentiate AD from bvFTD. In patients with the PPA pattern on imaging, the underlying cause (either FTD or AD) could be determined with a sensitivity/specificity rate of 88/82%. SPM analysis concurred that different regions of the olfactory circuit were affected in patients suffering from AD PPA or bvFTD PPA.

Conclusion: Metabolic dysfunction in the olfactory circuit is different in various neurodegenerative disorders. Further investigation of the correlations between the cerebral metabolism and the mechanisms which drive olfactory dysfunction is needed.

Keywords: Alzheimer’s disease; FDG PET; Frontotemporal dementia; Neurodegenerative disorders; Neuroimaging; Olfactory system.

MeSH terms

  • Aged
  • Alzheimer Disease* / diagnostic imaging
  • Alzheimer Disease* / metabolism
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Female
  • Fluorodeoxyglucose F18*
  • Frontotemporal Dementia* / diagnostic imaging
  • Frontotemporal Dementia* / metabolism
  • Humans
  • Male
  • Middle Aged
  • Olfactory Pathways / diagnostic imaging
  • Olfactory Pathways / metabolism
  • Positron Emission Tomography Computed Tomography* / methods
  • Prospective Studies
  • Radiopharmaceuticals

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals